Status:
COMPLETED
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Pfizer
Conditions:
HIV Infection
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV\< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncomp...
Eligibility Criteria
Inclusion
- HIV-1 infection
- maraviroc-naives patients
- CD4 less than 350 cells/mm3
- viral load less than 50 cp/mL and CD4 earning less than 100 cells/mm3 during last 24 months
Exclusion
- HIV-2 infection
- X4 tropism at inclusion
- pregnancy and breast feeding
- interferon, immunomodulatory drugs treatment or anti-HIV vaccines and chemotherapy
- hypersensibility of peanut or soya
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00944541
Start Date
September 1 2009
End Date
January 1 2011
Last Update
December 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
French National Agency for Research on AIDS and Viral Hepatits
Paris, France, 75013